Related Experiment Videos
The suppression of puerperal lactation with bromocryptine
Acta Obstetricia Et Gynecologica Scandinavica
|January 1, 1977
Summary
Brom-ergocryptine effectively suppresses postpartum lactation, reducing breast pain and congestion without significant side effects. This study investigated its therapeutic value in normal women, comparing drug recipients to a control group.
Area of Science:
- Reproductive Endocrinology
- Pharmacology
Background:
- Puerperal lactation can cause discomfort and is sometimes medically managed.
- Prolactin is a key hormone in lactation, with its regulation being complex postpartum.
Purpose of the Study:
- To evaluate the efficacy and safety of 2-Br-alpha-ergocryptine in suppressing puerperal lactation.
- To assess hormonal changes (FSH, oestradiol) and alpha-lactalbumin levels during lactation suppression.
Main Methods:
- A randomized controlled trial involving 30 normal women.
- 16 women received 2-Br-alpha-ergocryptine; 14 served as controls.
- Hormonal and protein marker measurements in a subset of participants.
Main Results:
- 2-Br-alpha-ergocryptine effectively suppressed milk production and alleviated breast pain.
- Minimal rebound lactation and no significant side effects were observed.
- The expected inverse relationship between prolactin and FSH was not evident in the early postpartum period.
Conclusions:
- 2-Br-alpha-ergocryptine is a safe and effective option for suppressing puerperal lactation.
- Postpartum hormonal dynamics, particularly concerning prolactin and FSH, may differ from non-pregnant states.
- Alpha-lactalbumin levels rise postpartum but do not differentiate between lactating and non-lactating women in this study.